Results 71 to 80 of about 1,761 (189)

Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis, Treatment, and Prevention

MedComm, Volume 7, Issue 3, March 2026.
This review focuses on the clinical features, molecular mechanisms, treatment methods, and preventive measures of the VZV, with the aim of providing a theoretical basis for the development of new treatment and prevention methods for HZ. ABSTRACT Varicella zoster virus (VZV) is a ubiquitous human herpesvirus that establishes lifelong latency and causes ...
Lei Peng, Honghao Song, Tianying Li, Yuqing Ma, Chen Yan, Yuhan Cao, Kaiqiang Sun, Chaofeng Han, Hongbin Yuan   +8 more
wiley   +1 more source

A Quality Improvement Initiative to Manage Shingrix Vaccine Inventory in Ambulatory Clinics

, 2020
Background: Inventory control practices for adult vaccines, specifically Shingrix, in ambulatory clinics are not well known or researched. This quality improvement project takes place at a small healthcare organization consisting of a hospital and ...
Colburn, Tracy
core  

Recombinant Glycoprotein E of Varicella Zoster Virus Contains Glycan-Peptide Motifs That Modulate B Cell Epitopes into Discrete Immunological Signatures [PDF]

, 2019
A recombinant subunit vaccine (Shingrix®) was recently licensed for use against herpes zoster. This vaccine is based on glycoprotein E (gE) of varicella zoster virus (VZV), the most abundantly expressed protein of VZV, harboring sites for N- and O ...
Risinger, Christian, Sihlbom, Carina, Risinger, C., Olofsson, Sigvard,, Bergström, Tomas, Sigvard Olofsson, Ebba Samuelsson, Olofsson, Sigvard, Samuelsson, Ebba,, Göran Larson, Ola Blixt, Larson, Göran, Sihlbom, C.,, Nordén, Rickard,, Larson, Göran,, Bergström, Tomas,, Blixt, O., Rickard Nordén, Nilsson, Jonas,, Nilsson, Jonas, Tomas Bergström, Carina Sihlbom, Blixt, Ola, Jonas Nilsson, Christian Risinger, Nordén, Rickard, Samuelsson, Ebba   +26 more
core   +1 more source

Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019

Human Vaccines & Immunotherapeutics, 2021
Shingrix (Recombinant zoster vaccine, RZV) was approved in October 2017 in the United States (US) for the prevention of herpes zoster in adults aged 50 years and older.
Brandon J. Patterson, Chi-Chang Chen, Catherine B. McGuiness, Lisa I. Glasser, Kainan Sun, Philip O. Buck   +5 more
doaj   +1 more source

Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients

British Journal of Haematology, Volume 208, Issue 6, Page 2288-2292, June 2026.
Takaaki Ono, Takashi Okada, Ryo Ikeda, Mitsuru Yamashita, Katsumi Koyauchi, Fumisato Takagi, Miwa Adachi, Tomonari Takemura, Kozue Mitsui, Yasuyuki Nagata   +9 more
wiley   +1 more source

Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies

European Journal of Haematology, Volume 116, Issue 3, Page 204-214, March 2026.
ABSTRACT Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in CLL is multifactorial: neoplastic B cells impair humoral immunity, T cells are functionally exhausted, and ...
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization

European Journal of Haematology, Volume 116, Issue 1, Page 14-22, January 2026.
ABSTRACT Background Herpes zoster (HZ), resulting from reactivation of latent varicella‐zoster virus (VZV), imposes a significant burden on immunocompromised patients, particularly those with hematological malignancies and recipients of hematopoietic stem cell transplants (HSCT).
Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Santino Caserta, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Recombinant Zoster Vaccine Associated with a Reduced Risk of Dementia Onset among US Beneficiaries ≥65 Years of Age

Alzheimer's &Dementia, Volume 21, Issue S7, December 2025.
Abstract Background Research showing lower risk of all‐cause dementia, Alzheimer’s Disease (AD), and vascular dementia (VD) with herpes zoster vaccination was based on one vaccine no longer marketed in the US. We evaluated the risk of dementia among US Medicare beneficiaries ≥65 years‐old who received recombinant zoster vaccine (RZV) relative to ...
Susan dosReis, Phuong Tran, Kareshma Mohanty, Alejandro Amill‐Rosario, Abree Johnson, Kathleen Ryan, Hannah Alsdurf, Driss Oraichi, Sofia B Pinto, Huifeng Yun   +9 more
wiley   +1 more source

Vacina contra o herpes zoster em Portugal

Revista Portuguesa de Medicina Geral e Familiar, 2020
Herpes zoster (HZ), também conhecido por zona, é uma doença causada pela reativação do vírus varicella zoster (VZ). O aumento da idade pode ser um fator de risco para HZ e as suas maiores complicações são a nevralgia pós-herpética (NPH) e o herpes ...
Margarida Gil Conde, Raquel Carmona Ramos   +1 more
doaj   +1 more source

Clinical progress note: Varicella Zoster

Journal of Hospital Medicine, Volume 20, Issue 12, Page 1348-1350, December 2025.
Abstract Varicella Zoster virus (VZV) is the etiologic agent responsible for varicella and herpes zoster (shingles). Nonimmune children and adults acutely infected with VZV typically experience a vesicular and pruritic rash that progresses from the face and trunk and generalizes to the extremities, accompanied by an oral enanthem along with symptoms of
Sirey Zhang, Adam L. Hersh, T. W. Jones
wiley   +1 more source